Coronavirus Disease-19: Vaccine Production and Development
Keywords:
Coronavirus disease-19; SARS-CoV-2; vaccine; herd immunity; vaccine developmentAbstract
The coronavirus disease (COVID-19) pandemic, which emerged in Wuhan, China, in late December 2019, is now rampantly spreading worldwide. There is a serious need for ultimate treatment of the disease, to stop the spread of the virus globally. In these unprecedented times, vaccines can play a pivotal role in strengthening the immunity of the community. Many drugs are being prescribed in hospital setups to treat the disease caused by the virus. Most of these drugs act as tools for symptomatic relief and palliative care in individuals. A noteworthy drug, favipiravir is being used in some countries like India, for COVID-19 positive patients, who have been hospitalized, in a debilitated state. However, drugs provide a cure at an individual level, but to control such a massive pandemic, a safe and efficacious vaccine is needed. Vaccines are the tools that have a huge impact on “herd immunity.” Not only the researchers but also the general public are eagerly anticipating the development of the vaccine so that they can be relieved of the multiple lockdowns and can rest assured. Unless a safe and efficacious vaccine against SARS-CoV-2 is developed, there is always a risk of new outbreaks of the disease. This article highlights some important points that help us feed the curiosities, with information on, what is a vaccine? Why do we need a vaccine for COVID-19? How will the vaccine develop?
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Asian Pacific Journal of Health Sciences applies the Creative Commons Attribution (CC-BY) license to published articles. Under this license, authors retain ownership of the copyright for their content, but they allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. Appropriate attribution can be provided by simply citing the original article.